Expert Considerations to Maximize the Clinical Benefits of Targeted Therapies in Patients With Relapsed/Refractory DLBCL is a hybrid CME symposium in which a panel of distinguished experts will explore the latest data regarding current and emerging therapeutic strategies for the management of relapsed/refractory (R/R) DLBCL. The program includes a didactic lecture on risk assessment, the latest clinical trial data for new and emerging targeted agents, and approaches for the management of treatment-related adverse events. In the “Hot Seat” portion of the program, the moderator will ask a series of clinically important questions.
June 3, 2022 | 7:00 pm – 9:00 pm CDT | Hilton Chicago, IL
